Navigation Links
Amylin Pharmaceuticals Reports First Quarter Financial Results
Date:4/21/2008

eriod in 2007.

Revenues under collaborative agreements were $18.5 million for the quarter ended March 31, 2008, which includes cost-sharing payments of $17.4 million, compared to $10.0 million, which includes cost-sharing payments of $8.9 million for the same period in 2007. The increase primarily reflects higher cost-sharing payments from Eli Lilly and Company to equalize development expenses for exenatide once weekly and BYETTA.

Selling, general and administrative expenses were $98.2 million for the quarter ended March 31, 2008, compared to $87.8 million for the same period in 2007. The increase primarily reflects promotional expenses for BYETTA, SYMLIN, exenatide once weekly market development and increases in infrastructure to support the Company's growth.

Research and development expenses increased to $77.2 million for the quarter ended March 31, 2008, compared to $59.6 million for the same period in 2007. The increase primarily reflects increased expenses for once weekly exenatide, and investment in the Company's early-stage obesity programs and drug delivery capabilities. Non-GAAP, net research and development expenses net of cost-sharing payments increased to $59.8 million for the quarter ended March 31, 2008, compared to $50.7 million for the same period in 2007.

Collaborative profit sharing, which represents Lilly's share of the gross margin for BYETTA, was $69.9 million for the quarter ended March 31, 2008, compared to $66.9 million for the same period in 2007.

Interest and other income, net decreased to $1.3 million for the quarter ended March 31, 2008, compared to $8.1 million for the same period in 2007. The decrease primarily reflects higher interest expense due to the Company's $575 million convertible debt issuance in June 2007 and the Company's $125 million term loan entered into in December 2007.

Net loss for the quarter ended March 31, 2008 was $68.8 million, or $0.51 per share, compared to $49.4 million,
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
2. Amylin Pharmaceuticals to Webcast Third Quarter Results
3. Amylin Pharmaceuticals to Webcast Conference Call
4. Amylin Pharmaceuticals to Present at Research & Development Day
5. Xenome Enters Into Joint Research Collaboration to Discover Novel Peptide Therapeutics with Amylin Pharmaceuticals
6. Amylin Pharmaceuticals Reports 2007 Financial Results
7. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
8. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
9. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2013)... Forney, United States (PRWEB) May 25, 2013 ... oldest and largest underground shelter company in the ... and composite underground structures for over 35 years. ... of PROTECTION, U.S. Handbook of NBC Weapon Fundamentals ... is the United States’ bible on shelter engineering. ...
(Date:5/25/2013)... (PRWEB) May 25, 2013 Absolute Surgical Specialists, ... many of the NALA’s businesses throughout the country participating in ... to participate in the nationwide event as he understands what ... Colonel in the Army. He said, “I wanted to give ... I serve, but I live here too.” , Shop Local ...
(Date:5/25/2013)... 25, 2013 The latest report ... irritable bowel syndrome (IBS) to bloating, constipation, diarrhea ... most long-lasting, embarrassing, frustrating and difficult health issues ... digestive health have provided a cure for ... factors contributing to digestive health issues, a healthy ...
(Date:5/25/2013)... 2013 According to a new ... 2013–2018", published by MarketsandMarkets is expected to reach ... 5.54% which analyzes and studies the major market ... Asia, and Rest of the World. , Browse:, ... , 87 Figures , ...
(Date:5/25/2013)... Vancouver, BC (PRWEB) May 25, 2013 ... of the most beautiful and powerful women that ever ... was felt by some of the most powerful men ... used many beauty remedies to keep her skin glowing ... treatments made with bees- wax, maringa oil and cyprus ...
Breaking Medicine News(10 mins):Health News:Radius Engineering International Inc. Offers Tools to Stay Safe and Recover From Any Disaster 2Health News:Radius Engineering International Inc. Offers Tools to Stay Safe and Recover From Any Disaster 3Health News:Dr. Craig Amshel of Absolute Surgical Specialists Offering Bowel Prep During the Shop Local for a Cause Event 2Health News:Natural Foods For Digestive Health Report and Video Published by BetterDigestion.org 2Health News:Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets 2Health News:Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets 3Health News:Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets 4Health News:The Cleopatra Lift - A New Non Surgical Option to Aging Offered by Vancouver Physician 2Health News:The Cleopatra Lift - A New Non Surgical Option to Aging Offered by Vancouver Physician 3
... Profitability, CARLSBAD, Calif., Feb. 12 Genoptix, Inc.,(Nasdaq: ... reported,revenues of $18.6 million for the fourth quarter ended ... $7.8 million for the comparable period,in 2006. For the ... of $59.3 million, an increase of 147% over revenues ...
... Feb. 12 AtriCure, Inc.,(Nasdaq: ATRC ), a ... products, announced today that David J. Drachman, President and,Chief ... Capital,Partners 20th Annual OC Growth Stock Conference at the ... February 20th at 2:00 p.m.,PT., A live web ...
... of anxiety may cause women with ductal carcinoma in ... cancer, to overestimate their risk of recurrence or dying ... at Dana-Farber Cancer Institute in Boston. , "Although DCIS ... DCIS develop inaccurate risk perceptions," said Ann Partridge, MD, ...
... answers the research offers , , TUESDAY, Feb. 12 ... one of the most pressing questions in critical care ... open the partially collapsed lungs of people being treated ... , Unfortunately, that question has not been definitively answered. ...
... cancer specialists at Jeffersons Kimmel Cancer Center in Philadelphia ... for liver cancer. The therapy entails injecting tiny beads ... main artery while also blocking the blood supply feeding ... been approved by the federal Food and Drug Administration ...
... 50, 75 and 100 mcg/hr) Not Affected, ... Pharmaceuticals, Inc. said today that all lots of ... by PriCara in the United States and all ... the United States are being voluntarily,recalled as a ...
Cached Medicine News:Health News:Genoptix Reports Strong Financial Results for the Fourth Quarter and Full Year 2007 2Health News:Genoptix Reports Strong Financial Results for the Fourth Quarter and Full Year 2007 3Health News:Genoptix Reports Strong Financial Results for the Fourth Quarter and Full Year 2007 4Health News:Genoptix Reports Strong Financial Results for the Fourth Quarter and Full Year 2007 5Health News:Genoptix Reports Strong Financial Results for the Fourth Quarter and Full Year 2007 6Health News:Genoptix Reports Strong Financial Results for the Fourth Quarter and Full Year 2007 7Health News:Genoptix Reports Strong Financial Results for the Fourth Quarter and Full Year 2007 8Health News:AtriCure to Present at Roth Capital Partners 20th Annual OC Conference 2Health News:Anxiety linked to newly diagnosed DCIS patients' overestimation of breast cancer risks 2Health News: Respiratory Distress Treatment Studies Conflict 2Health News: Respiratory Distress Treatment Studies Conflict 3Health News:New Jefferson trial to test radiation-emitting beads against advanced liver cancer 2Health News:PriCara(TM) Recalls 25 mcg/hr DURAGESIC(R) (fentanyl transdermal system) CII Pain Patches 2
(Date:5/24/2013)...  BD (Becton, Dickinson and Company) (NYSE: BDX ... it will present at the Deutsche Bank 38 th ... 10:40 a.m. (ET). A live webcast of ... at www.bd.com/investors and will be available for replay ... BD is a leading global medical technology company ...
(Date:5/24/2013)... 24, 2013 Solta Medical, Inc. (NASDAQ: ... today reported Dr. Edward W. Knowlton ... Directors effective immediately.  Dr. Knowlton is the founder of Thermage, ... a director since 1996. "On behalf of the ... I would like to thank Ed for his tireless dedication ...
(Date:5/24/2013)... , May 24, 2013  Heska Corporation (NASDAQ: HSKA, "Heska" ... specialty products, announced today that Dr. Robert Grieve ... Jason Napolitano , executive vice president and ... MicroCap Conference, which is being held May 30, 2013 in ... Hyatt Hotel. The Company,s presentation is scheduled ...
Breaking Medicine Technology:Dr. Edward W. Knowlton Resigns as a Director of Solta Medical, Inc. 2Heska Corporation To Present At The Second Annual Marcum LLP MicroCap Conference 2
... as Associate MemberWASHINGTON, Jan. 13 The Association ... clinical outsourcing industry to regulators, biopharmaceutical clients, policy ... worldwide, today announced that it has elected Dr. ... William Sharbaugh as Chair-Elect. Dr. Winstanly, MBChB, Executive ...
... /PRNewswire-FirstCall/ - - Uroplasty, Inc. (Amex: ... study of Macroplastique for the treatment of female stress ... Journal of Urology . This is the first, large, ... Macroplastique to another bulking agent used in the control ...
Cached Medicine Technology:Dr. Derek Winstanly of Quintiles to Serve as 2009 ACRO Chair; Mr. William Sharbaugh of PPD to Be Chair-Elect 2Uroplasty Highlights Results From Clinical Study on Macroplastique(R) for the Treatment of Stress Urinary Incontinence 2Uroplasty Highlights Results From Clinical Study on Macroplastique(R) for the Treatment of Stress Urinary Incontinence 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: